224 results on '"Wöll, E."'
Search Results
2. Multizentrische, retrospektive Kohortenstudie zur Erhebung der Inzidenz der Medikamenten-assoziierten Kiefernekrose bei Patient:innen mit primär oder sekundär ossär metastasiertem Mammakarzinom
3. S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON-ELIGIBLE PATIENTS WITH NDMM (AGMT-MM02 TRIAL)
4. Neue zielgerichtete Therapien des Magenkarzinoms
5. Biomarkers in non-small cell lung cancer prevention
6. Regulation of Intracellular Calcium in Cultured Renal Epithelioid (MDCK-) Cells
7. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group
8. Local and central evaluation of HER2 positivity and clinical outcome in advanced gastric and gastroesophageal cancer: results from the AGMT GASTRIC-5 Registry
9. Molecular and functional aspects of anionic channels activated during regulatory volume decrease in mammalian cells*
10. Gastric cancer – ASCO 2010
11. 1-year follow-up findings from a phase II study of catumaxomab as part of a multimodal approach in patients with primarily resectable gastric cancer: V389
12. Safety and tolerability of Catumaxomab as part of a multimodal approach in patients with primarily resectable gastric cancer: V413
13. Gastric cancer
14. Perioperative therapy in gastric cancer
15. Increased CD133 expression in bone marrow of myelodysplastic syndromes
16. Cell shrinkage stimulates bradykinin-induced cell membrane potential oscillations in NIH 3T3 fibroblasts expressing the ras-oncogene
17. Altered cell volume regulation in ras oncogene expressing NIH fibroblasts
18. Mechanism of intracellular calcium oscillations in fibroblasts expressing the ras oncogene
19. Immunocytochemical Profile of Angiogenic Markers in Bone Marrow of Myelodysplastic Syndromes: O356
20. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer
21. Further analysis of ATP-mediated activation of K+ channels in renal epitheloid Madin Darby canine kidney (MDCK) cells
22. Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: Comparison with immunohistochemistry and clinico-pathological features: P761
23. Molecular typing of tumour specimens in NSCLC patients applying fluorescence in situ hybridization (FISH): P760
24. Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis
25. Accuracy and sensitivity of ACIS™ (Automated Cellular Imaging System) for the quantitation of immunohistochemically stained nuclear markers (p53, ki-67, p120) in cryostat sections of lung cancer specimens: 771
26. High efficacy of fluorescence in situ hybridisation (FISH) in the molecular screening of non-small-cell lung cancer (NSCLC): 488
27. The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study
28. A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results
29. A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results
30. Austrian real world data in elderly and younger metastatic pancreatic cancer patients: Interim results of a multicenter non-interventional study with nab-paclitaxel/gemcitabine
31. Gastrointestinal cancers – still many questions to be resolved
32. Real life registry data of primary localisation of a well-defined colon cancer population of western Austria (Salzburg, Tyrol and Vorarlberg), eastern Switzerland (St. Gallen and Graubünden) and Liechtenstein
33. P-286 - The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study
34. P-034 - Austrian real world data in elderly and younger metastatic pancreatic cancer patients: Interim results of a multicenter non-interventional study with nab-paclitaxel/gemcitabine
35. O-015 - A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results
36. Effects of serotonin on electrical properties of Madin-Darby canine kidney cells
37. Cardiovascular complications of cancer treatment: update CACOCA trial
38. 599P - Real life registry data of primary localisation of a well-defined colon cancer population of western Austria (Salzburg, Tyrol and Vorarlberg), eastern Switzerland (St. Gallen and Graubünden) and Liechtenstein
39. Update CACOCA Trial (cardiovascular complications of cancer treatment)
40. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
41. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
42. Long term cardiotoxicity in patients treated with chemotherapy and/or targeted drugs, a prospective non interventional trial
43. Oxaliplatin, Irinotecan, Bevacizumab followed by Docetaxel, Bevacizumab in Inoperable Gastric Cancer. A Multicenter Phase II Trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)
44. Triple induction chemotherapy and chemoradiotherapy in locally advanced esophageal cancer: Final results of a multicenter phase II trial
45. Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group
46. Uveal melanoma
47. Icln, An Ion Channel-Forming Protein Associated with Cell Volume Regulation
48. Effect of inhibitors of Na+/H+-exchange and gastric H+/K+ATPase on cell volume, intracellular pH and migration of human polymorphonuclear leucocytes
49. Modification of Cellular Ion Transport by the Ha-ras Oncogene: Steps towards Malignant Transformation
50. Activation of the Na+/H+-exchanger is NIH 3T3 fibroblasts expressing the Ha-ras oncogene requires stimulated calcium influx and is associated with rearrangement of the actin cytoskeleton
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.